Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel

References

• Inbar M, Merimsky O, Chaitchik S. (1997). Taxanes: A breakthrough in cancer chemotherapy. Harefuah, 133(1–2):31–6.
   PubMedGoogle Scholar
• Schiff PB, Fant J, Horwitz SB. (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277:665–7.
   PubMed Web of Science ®Google Scholar
• Schiff PB, Horwitz SB. (1981). Taxol stabilizes microtubules in mouse fibroblast cells. Biochemistry, 20:3247–52.
   PubMed Web of Science ®Google Scholar
• Haldar S, Chintapalli J, Croce CM. (1996). Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res, 56:1253–5.
   PubMed Web of Science ®Google Scholar
• Spencer CM, Faulds D. (1994). Paclitaxel—a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs, 48(5):794–847.
   PubMed Web of Science ®Google Scholar
• Ishitobi M, Shin E, Kikkawa N. (2001). Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel. Int J Clin Oncol, 6(1):55–8.
   PubMedGoogle Scholar
• Thigpen JT. (2000). Chemotherapy for advanced ovarian cancer: Overview of randomized trials. Semin Oncol, 27(3):11–6.
   PubMed Web of Science ®Google Scholar
• Chang AY, Rubins J, Asbury R, Boros L, Hui LF. (2001). Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol, 28(4):10–3.
   PubMed Web of Science ®Google Scholar
• Li KW, Dang W, Tyler BM, Troiano G, Thian T, Brem H, . (2003). Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Anticancer Res, 15(9):3441–7.
   Google Scholar
• Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Sprub T, . (2002). Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest, 10(9):1309–17.
   Google Scholar
• Rowinsky EK, Cazenave LA, Donehower RC. (1990). Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst, 82:1247–59.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, . (2005). Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmcol, 45:674–82.
   PubMed Web of Science ®Google Scholar
• Gallo JM, Li S, Guo P, Redd K, Ma J. (2003). The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res, 63:5114–7.
   PubMed Web of Science ®Google Scholar
• Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, . (2003). Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res, 9:2849–55.
   PubMed Web of Science ®Google Scholar
• Weiss R, Donehower RC, Wiernik PH. (1990). Hypersensitivity reactions from taxol. J Clin Oncol, 8:1263–8.
   PubMed Web of Science ®Google Scholar
• Friedland D, Gorman G, Treat J. (1993). Hypersensitivity reactions from taxol and etoposide. J Natl Cancer Inst, 85(24):2036.
   PubMed Web of Science ®Google Scholar
• Gregory R, DeLisa AF. (1993). Paclitaxel: A new antineoplastic agent for refractory ovarian cancer. Clin Pharm, 42:401–15.
   Google Scholar
• Fjallskog ML, Frii L, Bergh J. (1993). Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet, 342(8875):873.
   PubMed Web of Science ®Google Scholar
• Singla AK, Garg A, Aggarwal D. (2002). Paclitaxel and its formulations. Int J Pharm, 235:179–92.
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, . (2005). Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol, 23(25):6019–26.
   PubMed Web of Science ®Google Scholar
• Sharma A, Straubinger RM. (1994). Novel Taxol formulations: Preparation and characterization of Taxol-containing liposomes. Pharm Res, 11:889–95.
   PubMed Web of Science ®Google Scholar
• Gupte A, Ciftci K. (2004). Formulation and characterization of paclitaxel, 5-FU and paclitaxel + 5-FU microspheres. Int J Pharm, 276(1–2):93–106.
   PubMed Web of Science ®Google Scholar
• Liggins RT, Cruz T, Min W, Liang L, Hunter WL, Burt HM. (2004). Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: Biocompatibility and efficacy determinations in rabbits. Inflamm Res, 53(8):363–72.
   PubMed Web of Science ®Google Scholar
• Lundberg BB. (1997). A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol, 49(1):16–21.
   PubMed Web of Science ®Google Scholar
• Tarr BD, Sambandan TG, Yalkowsky SH. (1987). A new parenteral emulsion for the administration of Taxol. Pharm Res, 4(2):162–5.
   PubMed Web of Science ®Google Scholar
• Yegin BA, Benoît JP, Lamprecht A. (2006). Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev Ind Pharm, 32(9):1089–94.
   PubMed Web of Science ®Google Scholar
• Si-Shen F, Li M, Win KY, Guofeng H. (2004). Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem, 11(4):413–24.
   PubMed Web of Science ®Google Scholar
• Yang S, Gursoy RN, Lambert G, Benita S. (2004). Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of p-glycoprotein inhibitors. Pharm Res, 21(2):261–70.
   PubMed Web of Science ®Google Scholar
• Wang J, Mongayt D, Torchilin VP. (2005). Polymeric micelles for delivery of poorly soluble drugs: Preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target, 13(1):73–80.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Kante B, Lenaerts V, Scailteur V, Ronald M, Speiser P. (1980). Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci, 69(2):199–202.
   PubMed Web of Science ®Google Scholar
• Peppas LB, Blanchette JO. (2004). Nanoparticles and targeted systems for cancer therapy. Adv Drug Deliv Rev, 56:1649–59.
   PubMed Web of Science ®Google Scholar
• Bennis S, Chapey C, Couvreur P, Robert J. (1994). Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacryate nanospheres against multidrug-resistant cells in culture. Eur J Cancer, 30A(1):89–93.
   PubMed Web of Science ®Google Scholar
• Guerrero DQ, Allemann E, Fessi H, Doelker E. (1998). Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm, 24(12):1113–28.
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Aminabhavi TM. (2007). Chitosan nanoparticles for prolonged delivery of timolol maleate. Drug Dev Ind Pharm, 33(11):1254–62.
   PubMed Web of Science ®Google Scholar
• Graves RA, Poole D, Moiseyev R, Bostanian LA, Mandal TK. (2008). Encapsulation of indomethacin using coaxial ultrasonic atomization followed by solvent evaporation. Drug Dev Ind Pharm, 34(4):419–26.
   PubMed Web of Science ®Google Scholar
• Attivi D, Wehrle P, Ubrich N, Damge C, Hoffman M, Maincent P. (2005). Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug Dev Ind Pharm, 31(2):179–89.
   PubMed Web of Science ®Google Scholar
• Shi K, Cui F. (2009). Optimized formulation of high-pay load PLGA nanoparticles containing insulin–lauryl sulfate complex. Drug Dev Ind Pharm, 35(2):177–84.
   PubMed Web of Science ®Google Scholar
• Akhnazarova S, Kafaro V. (1982). Experiment optimization in chemistry and chemical engineering. Moscow: Mir House Publications.
   Google Scholar
• Bolton S. (1997). Pharmaceutical statistics: Practical and clinical applications. New York: Marcel Dekker.
   Google Scholar
• Levy MY, Benita S. (1990). Drug release from submicronized o/w emulsion: A new in vitro kinetic evaluation model. Int J Pharm, 66(1–3):29–37.
   Web of Science ®Google Scholar
• Barzegar-Jalali M, Adibkia K, Valizadeh H, Shadbad MRS, Nokhodchi A, Omidi Y, . (2008). Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci, 11(1):167–77.
   PubMed Web of Science ®Google Scholar
• Doluisio JT, Bilups NF, Tukker JJ, Crommelin DJA. (1969). Drug absorption I: An in-situ rat gut technique yielding realistic absorption rates. J Pharm Sci, 58:1197–8.
   Google Scholar
• Schurgers N, Bijdendijk J, Tukker JJ, Crommelin DJA. (1986). Comparison of four experimental techniques for studying drug absorption kinetics in the anesthetized rat in situ. J Pharm Sci, 75(2):117–9.
   PubMed Web of Science ®Google Scholar
• Singh AT, Jaggi M, Khattar D, Awasthi A, Mishra SK, Tyagi S, . (2008). A novel nanopolymer based tumor targeted delivery system for paclitaxel. J Clin Oncol, 26(15S):11095.
   Google Scholar
• Niu F, Roby KF, Rajewski RA, Decedue C, Subramaniam B. (2006). Polymeric drug delivery II: Polymeric matrices and drug particle engineering. Washington, DC: ACS Publications.
   Google Scholar
• Jani P, Halbert GW, Langridge J, Florence AT. (1990). Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J Pharm Pharmacol, 42(12):821–6.
   PubMed Web of Science ®Google Scholar